PATHOGENESIS OF FIBRINOLYSIS IN DEFIBRINATION SYNDROME: EFFECT OF HEPARIN ADMINISTRATION.
D000347:Afibrinogenemia; D001780:Blood Coagulation Tests; D003110:Colonic Neoplasms; D003850:Deoxyribonuclease I; D004211:Disseminated Intravascular Coagulation; D004358:Drug Therapy; D004791:Enzyme Inhibitors; D005165:Factor V; D005169:Factor VIII; D005342:Fibrinolysis; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D007122:Immunoelectrophoresis; D010958:Plasminogen; D013299:Streptodornase and Streptokinase; D013300:Streptokinase; D014859:Warfarin
D004791:Enzyme Inhibitors; C427184:recombinant factor VIII SQ; D014859:Warfarin; D005165:Factor V; D005169:Factor VIII; D010958:Plasminogen; D006493:Heparin; D013299:Streptodornase and Streptokinase; D003850:Deoxyribonuclease I; D013300:Streptokinase
AFIBRINOGENEMIA; BLOOD COAGULATION TESTS; COLONIC NEOPLASMS; DRUG THERAPY; ENZYME INHIBITORS; FACTOR V; FACTOR VIII; FIBRINOLYSIS; HEPARIN, THERAPEUTIC; IMMUNOELECTROPHORESIS; PLASMINOGEN; STREPTODORNASE AND STREPTOKINASE; WARFARIN